Free Newsletter
SPOTLIGHT: FDA asks for data on asthma meds
Free newsletter via e-mail
Tools
The FDA has asked the makers of several beta agonist drugs for more data from clinical trials so it can "further evaluate the safety" of the drugs when used to treat asthma. Once the data is collected, the agency will convene an advisory panel to evaluate the safety risks. Back in 2005, FDA alerted healthcare professionals and patients that the drugs might increase the risk of worsened wheezing in some patients. Release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: